Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: mlkr who wrote (2959)	6/23/2010 12:26:02 PM
From: Jibacoa	1 Recommendation Read Replies (1) \| Respond to of 3722

Yes, NBIX had another UG Thursday, after signing a deal with Boehringer to develop drug candidates for the treatment of Type II D.M., and was able to make another 52wks. H on Monday. <g> bigcharts.marketwatch.com It hasn't closed its May25 UG, but it seems with present general market's mood it will probably close the last one.<g> bigcharts.marketwatch.com NBIX said that with Boehringer's help, they plan to develop small molecule agonists that would activate GPR119, a G protein-coupled receptor located in the digestive system and pancreatic islet belt,and that way could stimulate insulin production. NBIX will get a $10M upfront payment and is also eligible to receive up to $225M in milestone payments.<g> As I have mentioned, the ACTAY is $7 But with some further good news, the stock could get to the $10 level.<g> bigcharts.marketwatch.com Bernard